Enalare Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Enalare Therapeutics is a private, pre-revenue biotech addressing acute respiratory depression through its novel compound, ENA-001. The drug acts as a ventilatory stimulant with a unique mechanism of action, aiming to treat respiratory depression irrespective of its cause, such as opioid overdose, other drug overdoses, or medical conditions. The company is advancing ENA-001 into additional clinical trials, targeting significant unmet needs in emergency medicine, anesthesiology, and neonatology. Its success hinges on demonstrating clinical efficacy and safety across multiple indications in a complex and evolving competitive landscape.

Acute Respiratory DepressionDrug OverdoseApnea of PrematurityPost-operative Care

Technology Platform

Novel chemical entity (ENA-001) acting as an agnostic ventilatory stimulant with a novel mechanism of action to treat respiratory depression irrespective of cause.

Opportunities

The escalating drug overdose epidemic, particularly involving polypharmacy, creates a dire need for a broad-spectrum treatment like ENA-001.

Additional significant markets exist in neonatal care for apnea of prematurity and in hospital settings for post-operative respiratory depression, where current options are limited.

Risk Factors

Clinical development risk is high as ENA-001 must prove effective and safe in complex, acute care settings.

Regulatory pathways for life-saving drugs in vulnerable populations are stringent.

Market adoption faces competition from entrenched, low-cost treatments like naloxone.

Competitive Landscape

Direct competition includes opioid antagonists (naloxone, approved 1971) and the benzodiazepine antagonist flumazenil (approved 1991), both of which are drug-class specific and have significant limitations. ENA-001's agnostic mechanism positions it as a potential first-in-class broad-spectrum respiratory stimulant, but it may face future competition from other novel stimulants in development.

More companies in Small Molecule Drugs →More companies in United States →